AC BioScience Immuno-Oncology Cancer Drug Clinical Trials

Swiss biotech company based at EPFL Innovation Park developing breakthrough immuno-oncology therapies. ACB1801, a tumor reversion agent, demonstrates 65% survival improvement when combined with anti-PD-1 drugs in melanoma models. Pipeline targets multi-billion dollar market with estimated peak sales of $2.2 billion and proof-of-concept expected in 2024.